Market Mover: Medpace (MEDP) Rises at Midday May 13
Equities Staff Follow |Shares of Medpace Holdings Inc (NASDAQ: MEDP) climbed 5.85% Friday.
As of 12:02:22 est, Medpace is currently sitting at $139.94 and has climbed $7.79 per share.
Medpace has moved 16.03% over the last 30 days and has moved YTD 38.80% based on the most recent close.
The company is set to release earnings on 2022-07-25.
For technical charts, analysis, and more on Medpace visit the company profile.
About Medpace Holdings Inc
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,400 people across 37 countries.
To get more information on Medpace Holdings Inc and to follow the company's latest updates, you can visit the company's profile page here: Medpace Holdings Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer